Browsing Tag
Merck & Co.
27 posts
Merck and Eisai announce major win as Welireg plus Lenvima delays progression in advanced renal cell carcinoma
Find out how Merck and Eisai’s Welireg + Lenvima combo redefines kidney cancer care after immunotherapy and what this major Phase 3 win means for investors.
Merck’s kidney cancer breakthrough hits one target—Will it be enough to change how doctors treat RCC?
Merck and Eisai’s new kidney cancer combination met a key Phase 3 goal. Discover what it means for patients, investors, and the oncology landscape.
Bladder cancer breakthrough: FDA gives Priority Review to Merck’s KEYTRUDA and KEYTRUDA QLEX + PADCEV combinations
Find out how Merck’s KEYTRUDA and new KEYTRUDA QLEX + PADCEV combinations are set to transform treatment for muscle-invasive bladder cancer — read more now
Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial
Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.
Kelun-Biotech reports strong Phase 3 data for sacituzumab tirumotecan in HR+/HER2- breast cancer
Kelun-Biotech’s sacituzumab tirumotecan doubled PFS in HR+/HER2- breast cancer. Find out what this means for patients, investors, and China’s ADC landscape.
Are AI-discovered vaccines the next big frontier in pharma?
AI-discovered vaccines are moving from hype to reality. See how Evaxion, BioNTech, DIOSynVax and Baseimmune are reshaping discovery—and why big pharma is buying.
Winrevair slashes early PAH worsening by 76% in phase 3 Hyperion, but can it reset first-year care?
Winrevair reduced PAH clinical worsening by 76% in phase 3 Hyperion. Learn how Merck’s results could reset first-year treatment guidelines today.
Why Merck’s MSD is paying up to $600m for Evaxion’s undisclosed vaccine candidate EVX-B3
MSD licenses Evaxion’s AI-discovered vaccine EVX-B3 with $7.5M upfront and up to $592M in milestones—why this risky biotech bet could redefine vaccines.
Can Merck’s new Keytruda injection delay biosimilar threats and change cancer care forever?
Find out how Merck’s newly FDA-approved Keytruda QLEX injectable version aims to improve cancer care with faster, more convenient treatment. Read on.
Can Merck’s strategy around Keytruda formulations delay the biggest patent cliff in pharma history?
Can Merck’s subcutaneous Keytruda strategy soften the 2028 patent cliff? Explore how the drugmaker is diversifying and preparing for the biggest loss of exclusivity in pharma.